Several studies have shown that metformin is associated with reduced cancer-related morbidity and mortality, due to the improvement of insulin sensitivity, or to the activation of AMP-activated protein kinase….

This study demonstrates for the first time that acetaminophen induces a significant increase in ambulatory blood pressure in patients with coronary artery disease.…

Study found eating moderate amounts of omega-3 fatty acids was beneficial for patients with periodontal disease. Patients with diabetes have increased incidence and severity of periodontal disease not accounted for by differences in the subgingival microbial infection. Poor glycemic control has been consistently associated with periodontal disease severity….

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study found that combining linagliptin treatment with a sulfonylurea (SU) in diabetic patients was well tolerated and produced statistically significant and clinically relevant A1c reductions….

Barbers in Texas showed that they can participate in healthcare by helping to screen and reduce blood pressure. A cadre of barbers, true to their healthcare-provider heritage, participated in a hypertension-screening outreach experiment that helped many of their customers with hypertension to get their blood pressures under control….

A novel insulin that releases over several days showed similar efficacy to standard insulin but without an advantage for hypoglycemia in its first full phase III study….

However, as diabetes has surged actual number of cases rose, review of U.S. data found….

Just this week the CDC announced that as many as 1 in 3 U.S. adults could have diabetes by 2050 if current trends continue: that’s not 1 in 3 born after 2000, that is 1 of every 3 adults period. It is estimated that there will be 420 million residents …

By Iriny Nashed, PharmD Candidate Just when we thought we had it all figured out when it comes to diabetes management, we find there are not only new drugs on the horizon but new classes of medications that might just change the entire outlook on diabetes treatments.

  OVERVIEW: Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. The company recently submitted a New Drug Application to the …